Recent Analysts’ Ratings Updates for Aptose Biosciences (APTO)

Several brokerages have updated their recommendations and price targets on shares of Aptose Biosciences (NASDAQ: APTO) in the last few weeks:

• 2/12/2025 – Aptose Biosciences had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
• 2/9/2025 – Aptose Biosciences is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 2/1/2025 – Aptose Biosciences is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 1/24/2025 – Aptose Biosciences is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 1/16/2025 – Aptose Biosciences is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 1/10/2025 – Aptose Biosciences had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
• 1/8/2025 – Aptose Biosciences is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 12/31/2024 – Aptose Biosciences is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 12/23/2024 – Aptose Biosciences is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 12/15/2024 – Aptose Biosciences is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

Aptose Biosciences Stock Up 27.0 %

APTO stock opened at $0.23 on Thursday. Aptose Biosciences Inc. has a twelve month low of $0.13 and a twelve month high of $2.12. The firm has a market capitalization of $13.77 million, a PE ratio of -0.08 and a beta of 0.88. The stock has a 50-day simple moving average of $0.21 and a two-hundred day simple moving average of $0.32.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp boosted its holdings in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the period. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.